Optometry Educational Dinner | Dry ARM and non-exudative macular neovascularisation
Event description
The Optometry Educational Dinner Updates in Primary Eyecare is brought to you by The Layton Vision Foundation (LVF) and the LVF Ophthalmology Research Centre.
The topic and presentation covered for our third educational dinner is Dry ARM and non-exudative macular neovascularisation: imaging standards and new intravitreal treatment options.
Various imaging techniques are used to diagnose and monitor AMD, and while there are no specific imaging standards exclusively for AMD, there are commonly employed imaging modalities. We will discuss and explore the latest intravitreal treatment options highlighting the choice of treatment depends on the specific type and stage of AMD, as well as individual patient factors.
Our event has been accredited by Optometry Australia for Continuing Professional Development (CPD) points, that includes clinical, therapeutic and interactive points of 2.5T.i hours.
In addition to this, you will receive a Certificate of Attendance on the evening, with the Topic, a short description of presentation for your reference and record to accumulate towards your CPD Points.
Please note the Registration Desk will be open from 6.30pm with official proceedings set to commence at 7pm. We plan to wrap up and close by 9pm.
Our Presenter - Professor Christopher Layton:
Professor Christopher Layton (Dr Chris) is a private Clinical Ophthalmologist, Rhodes Scholar and a national leader in innovative ophthalmology. His expertise is in macular disease, lens surgery and minimally invasive glaucoma interventions. He completed optometry at QUT, ophthalmology in Queensland, Oxford and London, subspecialty training in retinal disease at the Royal Brisbane Hospital and holds a PhD in diabetic retinopathy from Oxford University. Professor Layton is a Rhodes Scholar and founding director of the LVF Ophthalmology Research Centre. He is also CEO of Ocugene, a Queensland based biotech start-up which is commercialising his gene therapy technology targeting macular degeneration, uveitis and choroidal melanoma.
Register today so you don't miss out on your place, as it is limited to 60 places. If you have any questions or query, please contact Janelle Bostock on E:j.bostock@laytonfoundation.org.au